September 1, 2003

For Immediate Release

Tissue Engineering Market Growth Still Explosive, with Hundreds of Companies in Pursuit, According to New Report from MedMarket Diligence

FOOTHILL RANCH, CA— Annual market growth rates over 30% will prevail despite challenges in the development of tissue engineered products for treatment of degenerative disorders, trauma and injury. According to a new report from MedMarket Diligence, huge opportunities remain available for tissue engineering in a wide variety of clinical segments including diabetes, liver disease, organ reconstitution, kidney failure, urology, neurology (including acute traumatic damage and chronic disorders), cardiology, vascular reconstruction, musculoskeletal, skin disorders, chronic wounds and cosmetic surgical reconstruction.

“In a market where roughly $4.5 billion has been invested, the opportunity for additional investment has been challenged,” says Patrick Driscoll, President of MedMarket Diligence, “yet new financing has nonetheless happened for companies like Geron, Osiris Therapeutics, BresaGen, ViaCell, NeuralStem, NeuroNova, Aastrom Biosciences, Layton Bioscience, MorphoGen Pharmaceuticals and StemCells.”  The reason for this, says Driscoll, is that approved skin and musculoskeletal applications are demonstrating market success, and many more clinical applications will be commercially realized in the next few years.

The MedMarket Diligence report examines the status of technologies, applications and markets for tissue engineering and transplantation products. The report reviews therapeutic technologies under various stages of development at several hundred companies, and profiles over 150. Products being developed address major causes of death and disease spanning applications in cardiovascular, neurological, orthopaedic, skin, organ and others. The report details the status of product development and assesses the current and forecast market for tissue engineering and transplantation products. Details on the report can be found at

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries.  In addition to medical technology reports, MedMarket Diligence publishes MedMarkets, which analyzes the market implications of new medical technology, and publishes dedicated reports on technology markets.  For more information on MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, e-mail, or visit the Web site at to view a sample issue of MedMarkets.